636 related articles for article (PubMed ID: 16831966)
21. Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants.
Castro-Martínez XH; García-Ruiz PJ; Martínez-García C; Martínez-Castrillo JC; Vela L; Mata M; Martínez-Torres I; Feliz-Feliz C; Palau F; Hoenicka J
Parkinsonism Relat Disord; 2018 Apr; 49():100-103. PubMed ID: 29361389
[TBL] [Abstract][Full Text] [Related]
22. Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors.
De Sousa SMC; Baranoff J; Rushworth RL; Butler J; Sorbello J; Vorster J; Thompson T; McCormack AI; Inder WJ; Torpy DJ
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31580439
[TBL] [Abstract][Full Text] [Related]
23. Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease.
Staubo SC; Fuskevåg OM; Toft M; Lie IH; Alvik KMJ; Jostad P; Tingvoll SH; Lilleng H; Rosqvist K; Størset E; Odin P; Dietrichs E; Dietrichs ES
Eur J Neurol; 2024 Feb; 31(2):e16144. PubMed ID: 37955562
[TBL] [Abstract][Full Text] [Related]
24. Impulse Control Disorders in the Polish Population of Patients with Parkinson's Disease.
Toś M; Grażyńska A; Antoniuk S; Siuda J
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629758
[No Abstract] [Full Text] [Related]
25. Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists.
Bienfait KL; Menza M; Mark MH; Dobkin RD
J Clin Neurosci; 2010 Apr; 17(4):539-40. PubMed ID: 20171891
[TBL] [Abstract][Full Text] [Related]
26. Impulse control and related disorders in Parkinson's disease.
Weintraub D; Nirenberg MJ
Neurodegener Dis; 2013; 11(2):63-71. PubMed ID: 23038208
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow-up of impulse control disorders in Parkinson's disease.
Mamikonyan E; Siderowf AD; Duda JE; Potenza MN; Horn S; Stern MB; Weintraub D
Mov Disord; 2008 Jan; 23(1):75-80. PubMed ID: 17960796
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal analysis of impulse control disorders in Parkinson disease.
Corvol JC; Artaud F; Cormier-Dequaire F; Rascol O; Durif F; Derkinderen P; Marques AR; Bourdain F; Brandel JP; Pico F; Lacomblez L; Bonnet C; Brefel-Courbon C; Ory-Magne F; Grabli D; Klebe S; Mangone G; You H; Mesnage V; Lee PC; Brice A; Vidailhet M; Elbaz A;
Neurology; 2018 Jul; 91(3):e189-e201. PubMed ID: 29925549
[TBL] [Abstract][Full Text] [Related]
29. A Multicenter Comparative Study of Impulse Control Disorder in Latin American Patients With Parkinson Disease.
Ramírez Gómez CC; Serrano Dueñas M; Bernal O; Araoz N; Sáenz Farret M; Aldinio V; Montilla V; Micheli F
Clin Neuropharmacol; 2017; 40(2):51-55. PubMed ID: 28288482
[TBL] [Abstract][Full Text] [Related]
30. Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
Lee JY; Jeon B; Koh SB; Yoon WT; Lee HW; Kwon OD; Kim JW; Kim JM; Ma HI; Kim HT; Baik JS; Cho J;
J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):30-37. PubMed ID: 30361296
[TBL] [Abstract][Full Text] [Related]
31. [Hypersexuality and other impulse control disorders in Parkinson's disease].
Nelis EA; Berendse HW; van den Heuvel OA
Ned Tijdschr Geneeskd; 2016; 160():A9359. PubMed ID: 26732226
[TBL] [Abstract][Full Text] [Related]
32. Clinical features associated with impulse control disorders in Parkinson disease.
Pontone G; Williams JR; Bassett SS; Marsh L
Neurology; 2006 Oct; 67(7):1258-61. PubMed ID: 17030761
[TBL] [Abstract][Full Text] [Related]
33. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease.
Lee JY; Kim JM; Kim JW; Cho J; Lee WY; Kim HJ; Jeon BS
Parkinsonism Relat Disord; 2010 Mar; 16(3):202-7. PubMed ID: 20018549
[TBL] [Abstract][Full Text] [Related]
34. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies.
Hassan A; Bower JH; Kumar N; Matsumoto JY; Fealey RD; Josephs KA; Ahlskog JE
Parkinsonism Relat Disord; 2011 May; 17(4):260-4. PubMed ID: 21310646
[TBL] [Abstract][Full Text] [Related]
35. Impulse control disorders in Parkinson's disease.
Marques A; Durif F; Fernagut PO
J Neural Transm (Vienna); 2018 Aug; 125(8):1299-1312. PubMed ID: 29511827
[TBL] [Abstract][Full Text] [Related]
36. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease.
Smith KM; Xie SX; Weintraub D
J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):864-70. PubMed ID: 26534930
[TBL] [Abstract][Full Text] [Related]
37. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease.
Kujawa K; Leurgans S; Raman R; Blasucci L; Goetz CG
Arch Neurol; 2000 Oct; 57(10):1461-3. PubMed ID: 11030798
[TBL] [Abstract][Full Text] [Related]
38. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study.
Cornelius JR; Tippmann-Peikert M; Slocumb NL; Frerichs CF; Silber MH
Sleep; 2010 Jan; 33(1):81-7. PubMed ID: 20120624
[TBL] [Abstract][Full Text] [Related]
39. Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors.
Claassen DO; van den Wildenberg WP; Harrison MB; van Wouwe NC; Kanoff K; Neimat JS; Wylie SA
Pharmacol Biochem Behav; 2015 Feb; 129():19-25. PubMed ID: 25459105
[TBL] [Abstract][Full Text] [Related]
40. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
Razmy A; Lang AE; Shapiro CM
Arch Neurol; 2004 Jan; 61(1):97-102. PubMed ID: 14732626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
